Forxiga 10 mg film-coated tablets clinical trials
13 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic use (Phase IV)
proMoting Effective Renoprotection in Cardiac sURgery patients by Inhibition of SGLT-2
This study is looking at whether a medicine called Forxiga can help protect kidneys in people having heart surgery. It wants to see if Forxiga can reduce the chances of kidney problems happening after the operation.
For: AKINetherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3, randomised, double-blind, placebo-controlled study assessing the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin with or without metformin.
This study looks at a medicine called gliclazide MR to see if it helps people with type 2 diabetes whose blood sugar isn't well controlled, even when using other common diabetes medicines like dapagliflozin or metformin. It aims to see if it's safe and effective.
For: Type 2 Diabetes inadequately controlled with dapagliflozin with or without metforminBulgaria · Lithuania · Latvia - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A study comparing exposure of semaglutide and dapagliflozin dosed orally as mono-components versus in a fixed-dose combination
This study is looking at two medicines for type 2 diabetes, semaglutide and dapagliflozin. Researchers want to see how well the body uses these medicines when given separately, compared to when they are combined into one single tablet.
For: Diabetes Mellitus · Type 2Germany - Ongoing, recruitingTherapeutic use (Phase IV)
Evolution of proteinuria in renal transplant patients treated with Dapagliflozin for nephroprotection. DAPAGREFFE
This study is looking at how a medicine called Dapagliflozin (also known as Forxiga) affects kidney health in people who have had a kidney transplant. Researchers want to see if it can help protect their new kidney by reducing a certain protein in their urine.
For: chronic renal failureFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIb, Multicentre, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria
This study is looking at a new drug, balcinrenone, given with an existing drug, dapagliflozin (Forxiga), for people with long-term kidney disease and too much protein in their urine. It aims to see if this new combination helps protect the kidneys.
For: Chronic Kidney Disease and AlbuminuriaBulgaria · Austria · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial. (DAPAH-trial)
This study is looking at a medicine called Forxiga (dapagliflozin) for people with high blood pressure in their lungs (pulmonary hypertension). We want to see if it helps improve how well people can exercise and how their heart and lungs work.
For: Chronic thromboembolic pulmonary hypertension · Pulmonary arterial hypertensionDenmark - Ongoing, recruitingTherapeutic use (Phase IV)
Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.
This study is looking at how well different diabetes medicines, like Invokana and Forxiga, work and how safe they are for older people with type 2 diabetes. The main goal is to see if these medicines help control blood sugar without causing dangerously low levels.
For: Type 2 diabetes mellitusItaly - AuthorisedTherapeutic exploratory (Phase II)
SGLT2 INHIBITION (DAPAGLIFLOZIN) IN DIABETIC AND NON-DIABETIC HEMODIALYSIS PATIENTS WITH AND WITHOUT RESIDUAL URINE VOLUME: A PROSPECTIVE RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PHASE II TRIAL
This study looks at a medicine called dapagliflozin (Forxiga) for people on dialysis with kidney problems, both with and without diabetes. We want to see if it helps reduce a common heart issue called Left Ventricular Hypertrophy, which is when the heart muscle thickens.
For: Chronic Kidney Disease · Kidney Failure · Left Ventricular HypertrophyAustria - AuthorisedTherapeutic use (Phase IV)
Acetazolamide in combination with SGLT2i in patients with volume overload and acute heart failure
This study looks at a new way to treat acute heart failure, a condition where your heart struggles to pump enough blood. It combines existing heart medications (Jardiance, Forxiga) with another drug (Diamox) to see if this helps the body get rid of extra salt and water, which can build up during heart failure.
For: Acute Heart FailureBelgium - AuthorisedTherapeutic use (Phase IV)
Effects of sodium-glucose cotransporter 2 inhibition on the mechanisms of heart failure with preserved ejection fraction
This study is looking at how a common heart failure medicine called Forxiga works in people who have a specific type of heart failure. It aims to understand the drug's effects on the heart's pumping ability and structure, helping us learn more about how it helps patients.
For: Heart failure with preserved ejection fractionSpain - AuthorisedTherapeutic use (Phase IV)
Early use of dapagliflozin in patients with acute myocardial infarction and reduced ejection fraction: the randomized ARMYDA-9 Dapagliflozin trial
This study is looking at whether a drug called Forxiga can help people who have recently had a heart attack. Researchers will check if it can reduce damage to the heart muscle and improve overall health after three months.
For: Acute Myocardial InfarctionItaly - AuthorisedTherapeutic confirmatory (Phase III)
Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus
This study looks at how certain diabetes medications, called SGLT2 inhibitors, might affect the build-up of fatty deposits (atherosclerosis) in the heart's arteries after a heart attack. It aims to see if these medicines can slow down or stop this build-up in people with diabetes.
For: Myocardial Infarction · diabetes mellitusItaly - AuthorisedTherapeutic exploratory (Phase II)
SGL-TX-PTDM: SGLT2i effect on PTDM development and kidney allograft function in kidney transplant recipients: A randomized, double-blind, placebo controlled, national multicenter trial
This study looks at how a drug called Forxiga affects new diabetes and kidney health in people who've had a kidney transplant. It compares Forxiga to a dummy pill to see if it makes a difference over 6 to 12 months.
For: Kidney transplant recipientsDenmark